Search results for "PARKIN"

showing 10 items of 468 documents

The assessment of functional ability in patients with Parkinson's disease: the PLM-test and three clinical tests.

1997

This study assesses functional ability of Parkinson's disease (PD) patients by means of an objective movement analysis (the PLM-test) and three clinical tests. The correlation between the tests was also studied. The main object of this study was to detect and measure relevant disabilities in Parkinson's disease to obtain a clinical test battery.

AdultMaleClinical testsmedicine.medical_specialtyActivities of daily livingParkinson's diseasePosturePhysical Therapy Sports Therapy and RehabilitationDiseaseDisability EvaluationPhysical medicine and rehabilitationActivities of Daily LivingmedicineHumansFunctional abilityGaitPostural BalancePhysical Therapy ModalitiesAgedAged 80 and overAnalysis of VarianceParkinson DiseaseMiddle Agedmedicine.diseaseGaitTest (assessment)Physical therapyFemaleAnalysis of variancePsychologyLocomotionPsychomotor PerformancePhysiotherapy research international : the journal for researchers and clinicians in physical therapy
researchProduct

pBrain: A novel pipeline for Parkinson related brain structure segmentation

2020

[EN] Parkinson is a very prevalent neurodegenerative disease impacting the life of millions of people worldwide. Although its cause remains unknown, its functional and structural analysis is fundamental to advance in the search of a cure or symptomatic treatment. The automatic segmentation of deep brain structures related to Parkinson's disease could be beneficial for the follow up and treatment planning. Unfortunately, there is not broadly available segmentation software to automatically measure Parkinson related structures. In this paper, we present a novel pipeline to segment three deep brain structures related to Parkinson's disease (substantia nigra, subthalamic nucleus and red nucleus…

AdultMaleComputer scienceCognitive NeurosciencePipeline (computing)NeuroimagingSubstantia nigraImage processinglcsh:Computer applications to medicine. Medical informaticslcsh:RC346-429050105 experimental psychologyNeurologia03 medical and health sciences0302 clinical medicineImage Interpretation Computer-Assisted[INFO.INFO-IM]Computer Science [cs]/Medical ImagingImage Processing Computer-AssistedHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingSegmentationlcsh:Neurology. Diseases of the nervous systemAgedStructure (mathematical logic)Artificial neural networkbusiness.industry05 social sciencesBrainReproducibility of ResultsRegular ArticleParkinson DiseasePattern recognitionMiddle AgedMagnetic Resonance ImagingSubthalamic nucleusNeurologyFISICA APLICADAlcsh:R858-859.7Sistema nerviós MalaltiesFemaleNeurology (clinical)Artificial intelligencebusinessError detection and correctionLENGUAJES Y SISTEMAS INFORMATICOS030217 neurology & neurosurgery
researchProduct

A new method to calculate external mechanical work using force-platform data in ecological situations in humans: Application to Parkinson's disease

2016

Abstract Background and aim To accurately quantify the cost of physical activity and to evaluate the different components of energy expenditure in humans, it is necessary to evaluate external mechanical work ( W EXT ). Large platform systems surpass other currently used techniques. Here, we describe a calculation method for force-platforms to calculate long-term W EXT . Methods Each force-platform (2.46 × 1.60 m and 3.80 × 2.48 m) rests on 4 piezoelectric sensors. During long periods of recording, a drift in the speed of displacement of the center of mass (necessary to calculate W EXT ) is generated. To suppress this drift, wavelet decomposition is used to low-pass filter the source signal.…

AdultMaleExternal mechanical workPiezoelectric sensorComputer scienceParkinson's diseaseBiophysicsMédecine humaine et pathologieModels BiologicalSignalDisplacement (vector)Human physical activity03 medical and health sciences0302 clinical medicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]HumansOrthopedics and Sports MedicineForce platformPhysiologieSimulationenergy expenditure;external mechanical work;human physical activity;parkinson's disease;work efficiencySignal processing[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO][SCCO.NEUR]Cognitive science/NeuroscienceRehabilitationWork (physics)PendulumParkinson DiseaseWork efficiency030229 sport sciencesFilter (signal processing)Biomechanical PhenomenaCase-Control Studiesphysiology[ SCCO.NEUR ] Cognitive science/NeuroscienceExercise TestHuman health and pathologyEnergy expenditureEnergy Metabolism030217 neurology & neurosurgery
researchProduct

Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease

2003

Increased echogenicity of the substantia nigra (SN) on ultrasound is a typical sonographic finding in Parkinson's disease (PD). Sonographic signal intensity of the SN is related to tissue iron content with higher iron level being associated with increased echogenicity. Recent findings indicate that hyperechogenicity of the SN represents an important susceptibility factor for nigrostriatal degeneration. In this study we determined the prevalence of a characteristic ultrasound sign of Parkinson's disease in first-degree relatives of PD patients. Fourteen patients with sporadic PD and 58 of their relatives underwent neurological, neuropsychological, and ultrasound examination. In addition, fou…

AdultMaleFluorine RadioisotopesPathologymedicine.medical_specialtyParkinson's diseaseUltrasonography Doppler TranscranialCognitive NeuroscienceSubstantia nigraNeuropsychological TestsHypokinesiamedicineHumansGenetic Predisposition to DiseaseGenetic TestingDominance CerebralProblem SolvingDominance (genetics)business.industryPutamenUltrasoundEchogenicityParkinson DiseaseMiddle Agedmedicine.diseaseDihydroxyphenylalanineTranscranial DopplerSubstantia NigraNeurologyNerve DegenerationFemalemedicine.symptomPsychologybusinessTomography Emission-ComputedNeuroImage
researchProduct

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

2005

We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examinatio…

AdultMaleLevodopamedicine.medical_specialtyTime FactorsNeurologyParkinson's diseaseAdministration Oralparkinson's diesease clinical neurophysiology kinematicsKinematicsClinical neurophysiologyAntiparkinson AgentsLevodopaCentral nervous system diseaseBolus (medicine)Internal medicinemedicineHumansAgedbusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseBiomechanical PhenomenaSurgeryNeurologyCarbidopaCardiologyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessPsychomotor Performancemedicine.drug
researchProduct

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET

2009

Abstract Transcranial ultrasound (TCS) has been shown to reveal hyperechogenicity of the substantia nigra (SN) in Parkinsonian patients and in about 10% of healthy controls. It is hypothesized that SN hyperechogenicity in healthy subjects is a vulnerability marker for idiopathic Parkinson's disease (IPD). Although there is strong evidence that the echomarker results from increased local iron content, the exact pathophysiological mechanisms remain incompletely understood. Thus, prognostic impact can only be estimated. We examined 14 subjects with SN hyperechogenicity (SN+) (7 IPD patients and 7 controls) and 7 healthy controls without the echomarker (SN−) by a magnetic resonance imaging meth…

AdultMalePathologymedicine.medical_specialtyCognitive NeuroscienceSubstantia nigraReference ValuesmedicineHumansNeuronsmedicine.diagnostic_testbusiness.industryTissue inhomogeneityHealthy subjectsParkinson DiseaseMagnetic resonance imagingMiddle AgedEchoencephalographyMagnetic Resonance ImagingPathophysiologyDihydroxyphenylalanineTranscranial DopplerSubstantia NigraNeurologyPositron-Emission TomographyT2 relaxationIron contentFemaleRadiopharmaceuticalsbusinessNeuroImage
researchProduct

Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily.

2007

Abstract Objective To estimate prevalence of Parkinson's disease (PD) and other types of parkinsonism in the Aeolian Archipelago, Sicily. Methods We studied the frequency of PD and other types of parkinsonism in the Aeolian Archipelago (population 13,431). All potential cases were identified from available medical information sources. To ensure the completeness of the case-findings, a screening questionnaire was also mailed to residents aged 40 years and over. Subjects were considered prevalent if they fulfilled the SNES diagnostic criteria for PD, on prevalence day (January 1, 2001). Results We identified 17 patients with parkinsonism from medical sources, and 4 from mail-survey. Prevalenc…

AdultMalePediatricsmedicine.medical_specialtyParkinson's diseasePopulationMedical informationDiseaseSeverity of Illness IndexParkinsonian DisordersEpidemiologyEpidemiology parkinsonism prevalencemedicineHumanseducationSicilyAeolian archipelagoAgedAged 80 and overeducation.field_of_studybusiness.industryParkinsonismParkinson DiseaseMiddle Agedmedicine.diseaseHealth SurveysScreening questionnaireNeurologyPhysical therapyFemaleNeurology (clinical)Geriatrics and GerontologybusinessParkinsonismrelated disorders
researchProduct

Motor abnormalities and basal ganglia in first-episode psychosis (FEP)

2020

AbstractBackgroundMotor abnormalities (MAs) are the primary manifestations of schizophrenia. However, the extent to which MAs are related to alterations of subcortical structures remains understudied.MethodsWe aimed to investigate the associations of MAs and basal ganglia abnormalities in first-episode psychosis (FEP) and healthy controls. Magnetic resonance imaging was performed on 48 right-handed FEP and 23 age-, gender-, handedness-, and educational attainment-matched controls, to obtain basal ganglia shape analysis, diffusion tensor imaging techniques (fractional anisotropy and mean diffusivity), and relaxometry (R2*) to estimate iron load. A comprehensive motor battery was applied incl…

AdultMalePsychosismedicine.medical_specialtyAkathisiaBasal Ganglia03 medical and health sciences0302 clinical medicineInternal medicineBasal gangliaFractional anisotropyImage Processing Computer-AssistedmedicineHumansPsychomotor AgitationApplied Psychologymedicine.diagnostic_testbusiness.industryParkinsonismBrainMagnetic resonance imagingmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryMotor coordinationPsychiatry and Mental healthDiffusion Tensor ImagingPsychotic DisordersSchizophreniaCardiologyFemaleAtrophymedicine.symptombusiness030217 neurology & neurosurgeryDiffusion MRIPsychological Medicine
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

Urological dysfunctions in patients with Parkinson’s disease: clues from clinical and non-invasive urological assessment

2018

Abstract Background Autonomic nervous system dysfunction, common in patients with Parkinson’s disease (PD), causes significant morbidity and it is correlated with poor quality of life. To assess frequency of urinary symptoms in patients with PD, without conditions known to interfere with urinary function. Methods Non-demented PD patients were consecutively enrolled from the outpatients clinic of our department. Scales investigating motor and non-motor symptoms were carried out. Evaluation of urinary dysfunctions was carried out using the AUTonomic Scale for Outcomes in Parkinson’s disease (SCOPA-AUT) questionnaire. Patients underwent noninvasive urological studies (nUS), including uroflowme…

AdultMaleUrologic Diseasesmedicine.medical_specialtyNeurologyParkinson's diseaseUrinary systemAutonomic dysfunction030232 urology & nephrologyNon-motor symptomsUrinary symptomsDiseaseNon-motor symptomlcsh:RC346-429SCOPA-AUT03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesInternal medicinemedicineHumansNeurochemistryStage (cooking)lcsh:Neurology. Diseases of the nervous systemAgedbusiness.industryAUTonomic SCale for outcomes in Parkinson’s diseaseParkinson DiseaseGeneral MedicineMiddle AgedUrinary functionmedicine.diseaseAutonomic Nervous System DiseasesQuality of LifeParkinson’s diseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgeryBMC Neurology
researchProduct